Anzeige
❌
Mehr »
Donnerstag, 19.11.2026 - Börsentäglich über 12.000 News
Folge dem Geld: Methan im Fokus der COP31!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
IT

WKN: A42BHX | ISIN: CNE100007LG4 | Ticker:
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
IMPACT THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
IMPACT THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur IMPACT THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
00:01XFRA NEW INSTRUMENTS AVAILABLE ON 19.11.202657The following instruments on XETRA do have their first trading 19.11.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 19.11.2026 Aktien 1 US03703U1079 Anthropic PBC 2 SG1BA1000003...
► Artikel lesen
DiIMPACT THERAP-B Senaparib Approved for Marketing in EU2
IMPACT THERAPEUTICS Aktie jetzt für 0€ handeln
MoIMPACT THERAP-B (07630): INSIDE INFORMATION - APPROVAL BY THE EUROPEAN COMMISSION FOR MARKETING OF SENAPARIB1
03.11.IMPACT THERAP-B (07630): VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASE1
23.10.IMPACT THERAP-B (07630): VOLUNTARY ANNOUNCEMENT - POSTER PRESENTATION OF LATEST CLINICAL DATA FOR SENAPARIB AND PARP1-SELECTIVE INHIBITORS IMP1734 AND ...1
18.09.IMPACT THERAP-B (07630): VOLUNTARY ANNOUNCEMENT - POSITIVE CHMP OPINION FOR SENAPARIB, AS POTENTIAL FIRST-LINE MAINTENANCE TREATMENT OF ADVANCED EPITHELIAL ...-
18.09.IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer644For business and medical media onlyThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/Stephan Eder, CEO, Pharmanovia IMPACT...
► Artikel lesen
14.09.IMPACT THERAP-B (07630): 2026 INTERIM REPORT2
07.09.IMPACT THERAP-B (07630): VOLUNTARY ANNOUNCEMENT - INCLUSION IN THE STOCK LIST OF THE SHANGHAI-HONG KONG STOCK CONNECT AND THE SHENZHEN-HONG KONG STOCK ...1
03.09.IMPACT THERAP-B (07630): VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING BY THE EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER4
31.08.IMPACT THERAP-B (07630): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 20261
24.08.IMPACT THERAP-B (07630): VOLUNTARY ANNOUNCEMENT - INCLUSION AS A CONSTITUENT OF HANG SENG COMPOSITE INDEX1
19.08.IMPACT THERAP-B (07630): DATE OF BOARD MEETING-
12.08.IMPACT THERAP-B (07630): VOLUNTARY ANNOUNCEMENT - IMPACT THERAPEUTICS ANNOUNCES IMP2794 AS A PRECLINICAL CANDIDATE (PCC), A HIGHLY KAT6A-SPECIFIC PROTAC ...2
11.08.IMPACT THERAP-B (07630): PROFIT ALERT REDUCTION IN LOSS4
03.08.IMPACT Therapeutics grants Pharmanovia exclusive $488m rights to senaparib1
31.07.IMPACT THERAP-B (07630): TERMS OF REFERENCE OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS1
31.07.IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand506SHANGHAI, July 31, 2026 /PRNewswire/ -- IMPACT Therapeutics ("IMPACT") (07630.HK) is pleased to announce that it has entered into an exclusive partnership (the "Exclusive Partnership") with...
► Artikel lesen
31.07.Impact Therapeutics licenses senaparib to Pharmanovia1
30.07.IMPACT THERAP-B (07630): VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT WITH PHARMANOVIA FOR SENAPARIB IN EUROPE, MIDDLE EAST AND NORTH AFRICA, ...1
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1